uniQure Competitors

Ionis Pharmaceuticals (NASDAQ:IONS) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Insider & Institutional Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 78.3% of uniQure shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Ionis Pharmaceuticals has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Earnings and Valuation

This table compares Ionis Pharmaceuticals and uniQure's revenue, earnings per share (EPS) and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ionis Pharmaceuticals and uniQure's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for Ionis Pharmaceuticals and uniQure, as provided by MarketBeat.

Ionis Pharmaceuticals currently has a consensus price target of $57.4545, suggesting a potential upside of 38.54%. uniQure has a consensus price target of $68.4615, suggesting a potential upside of 115.49%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats uniQure on 9 of the 15 factors compared between the two stocks.

uniQure (NASDAQ:QURE) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Volatility and Risk

uniQure has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Institutional and Insider Ownership

78.3% of uniQure shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 2.8% of uniQure shares are owned by company insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares uniQure and Sarepta Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares uniQure and Sarepta Therapeutics' top-line revenue, earnings per share and valuation.

uniQure has higher earnings, but lower revenue than Sarepta Therapeutics. uniQure is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for uniQure and Sarepta Therapeutics, as reported by MarketBeat.

uniQure presently has a consensus target price of $68.4615, suggesting a potential upside of 115.49%. Sarepta Therapeutics has a consensus target price of $150.3810, suggesting a potential upside of 107.88%. Given uniQure's stronger consensus rating and higher probable upside, research analysts clearly believe uniQure is more favorable than Sarepta Therapeutics.

Summary

uniQure beats Sarepta Therapeutics on 8 of the 15 factors compared between the two stocks.

TG Therapeutics (NASDAQ:TGTX) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

65.7% of TG Therapeutics shares are owned by institutional investors. Comparatively, 78.3% of uniQure shares are owned by institutional investors. 13.2% of TG Therapeutics shares are owned by insiders. Comparatively, 2.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

TG Therapeutics has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for TG Therapeutics and uniQure, as provided by MarketBeat.com.

TG Therapeutics currently has a consensus price target of $63.3333, suggesting a potential upside of 56.57%. uniQure has a consensus price target of $68.4615, suggesting a potential upside of 115.49%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than TG Therapeutics.

Profitability

This table compares TG Therapeutics and uniQure's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares TG Therapeutics and uniQure's gross revenue, earnings per share (EPS) and valuation.

uniQure has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Summary

uniQure beats TG Therapeutics on 11 of the 15 factors compared between the two stocks.

uniQure (NASDAQ:QURE) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Institutional and Insider Ownership

78.3% of uniQure shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 2.8% of uniQure shares are held by insiders. Comparatively, 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

uniQure has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for uniQure and Perrigo, as provided by MarketBeat.com.

uniQure presently has a consensus price target of $68.4615, suggesting a potential upside of 115.49%. Perrigo has a consensus price target of $52.00, suggesting a potential upside of 22.09%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Perrigo.

Profitability

This table compares uniQure and Perrigo's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares uniQure and Perrigo's gross revenue, earnings per share and valuation.

Perrigo has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Summary

uniQure beats Perrigo on 8 of the 15 factors compared between the two stocks.

uniQure (NASDAQ:QURE) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and target prices for uniQure and Allakos, as provided by MarketBeat.com.

uniQure presently has a consensus price target of $68.4615, suggesting a potential upside of 115.49%. Allakos has a consensus price target of $181.50, suggesting a potential upside of 71.26%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than Allakos.

Institutional and Insider Ownership

78.3% of uniQure shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 2.8% of uniQure shares are held by insiders. Comparatively, 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

uniQure has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Earnings & Valuation

This table compares uniQure and Allakos' gross revenue, earnings per share and valuation.

Allakos has lower revenue, but higher earnings than uniQure. Allakos is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares uniQure and Allakos' net margins, return on equity and return on assets.

Summary

uniQure beats Allakos on 7 of the 13 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Volatility & Risk

Blueprint Medicines has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Blueprint Medicines and uniQure, as provided by MarketBeat.

Blueprint Medicines presently has a consensus target price of $112.40, suggesting a potential upside of 19.36%. uniQure has a consensus target price of $68.4615, suggesting a potential upside of 115.49%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Blueprint Medicines.

Earnings and Valuation

This table compares Blueprint Medicines and uniQure's revenue, earnings per share (EPS) and valuation.

uniQure has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

78.3% of uniQure shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by company insiders. Comparatively, 2.8% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Blueprint Medicines and uniQure's net margins, return on equity and return on assets.

Summary

uniQure beats Blueprint Medicines on 8 of the 14 factors compared between the two stocks.